Madison, WI, USA, & San Diego, CA, USA June 28, 2021 — Nimble Therapeutics and RayzeBio today announced the companies have entered a strategic collaboration

HOLLISTER, Calif., June 24, 2021 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production

PORT WASHINGTON, N.Y., June 1, 2021 /PRNewswire/ — Precision NanoSystems (PNI) has been acquired by Danaher Corporation’s Life Sciences platform. PNI is a global leader in technologies and solutions

MARLBOROUGH, Mass., April 15, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its initial

CODEX’s spatial phenotyping capabilities will contribute to HCA investigators’ ability to build comprehensive tissue maps. MARLBOROUGH, Mass. — March 23, 2021 — Akoya Biosciences, Inc., The Spatial

MINNEAPOLIS and AUSTIN, Texas, March 3, 2021  /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic

Cardiff, UK, March 3, 2021 ‒ TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed

Investment will bring Canada’s first centre of manufacturing excellence of nanomedicine-based RNA vaccines, gene therapies and cell therapies. At project completion early in 2023, the

Carterra, Inc., the world leader in label-free high throughput antibody screening and characterization, today announced that they have closed on a round of equity financing

December 2, 2020 – MOUNTAIN VIEW, California – FOR IMMEDIATE RELEASE Specific Diagnostics today announced that it has received ISO-13485 certification through the International Organization

Agena Bioscience®, a global provider of low-cost and high-throughput molecular testing solutions, today announced that its MassARRAY® SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2

PNI will use the investment to advance a cost-effective Made-in-Canada COVID-19 vaccine PNI offers expertise in self-amplifying mRNA vectors, lipid-based drug delivery systems and nanomedicine